Substance P stimulation of amylase release by isolated parotid cells and inhibition of substance P induction of salivation by vasoactive peptides.
Substance P stimulation of salivation in rats has been studied as has its in vitro enhancement of amylase release by isolated parotid cells. The extent of the stimulation on amylase release by isolated parotid cells was dependent upon the concentration of substance P, with the minimum effective concentration being 1 nM. The substance P effect was detectable within 1 min after incubation and lasted for at least 50 min. Substance P stimulation was demonstrable at 25--37 degrees C but not at 0 degrees C. Adrenocorticotropic hormone (ACTH), thyrotropin-releasing hormone (TRH), vasopressin and neurotensin had no effect on amylase release. These results suggest that substance P may act directly on the parotid cells. Examination of the salivary-stimulating activity of fragments of substance P showed that the C-terminal octapeptide and (pyroglutamyl)hexapeptide were active, although less potent than substance P, whereas its free acid, C-terminal tetra- and tri-peptides were inactive. Vasopressin, angiotensin II and neurotensin could inhibit substance P induced salivation, whereas TRH, ACTH and somatostatin had no effect. Amylase activity per unit volume of saliva was not changed by the injection of vasopressin, angiotensin II or neurotensin. These vasoactive peptides did not affect substance P stimulation of amylase release by isolated parotid cells. The results indicate that vasopressin, angiotensin II and neurotensin inhibit the action of substance P on salivation at sites other than the parotid cells.
D000109:Acetylcholine / Q000494:pharmacology; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000681:Amylases / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002766:Cholecystokinin / Q000494:pharmacology; D004745:Enkephalins / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009496:Neurotensin / Q000494:pharmacology; D010306:Parotid Gland / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D012463:Saliva / Q000378:metabolism*; D013004:Somatostatin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology; D000516:alpha-Amylases / Q000378:metabolism*
D004745:Enkephalins; D010446:Peptide Fragments; D014667:Vasopressins; D000804:Angiotensin II; D013373:Substance P; D009496:Neurotensin; D013004:Somatostatin; D000324:Adrenocorticotropic Hormone; D002766:Cholecystokinin; D000681:Amylases; D000516:alpha-Amylases; D000109:Acetylcholine; D004837:Epinephrine